Vision outcomes of a non-diffractive extended-vision intraocular lens implanted with mini-monovision

Session Details

Session Title: Extended-Depth-Of-Focus IOLs I

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:24

Venue: Free Paper Forum: Podium 1

First Author: : C.Balachandran AUSTRALIA

Co Author(s): :    S. Lee   D. Carson   J. Lemp-Hull                       

Abstract Details

Purpose:

To evaluate visual outcomes with bilateral minimonovision implantation of a new non-diffractive extended vision intraocular lens (Alcon DFT015)

Setting:

Multicenter, multicountry clinical trial sponsored by Alcon

Methods:

Subjects were bilaterally implanted with DFT015 targeting emmetropia (± 0.5 D). Based upon manifest refraction spherical equivalent (MRSE) at 6 months, subjects were categorized as minimonovision if MRSE difference between eyes was ≥0.5 D and MRSE in at least one eye was ≤-0.25 D. Binocular uncorrected distance (UDVA), intermediate (UIVA), and near visual acuity (UNVA), spectacle use, and quality of vision (QoV, McAlinden et al) were assessed. Additionally, spot images from a high dynamic range halo bench (4.5 mm aperture) were collected from simulated monovision of DFT015 with one IOL set to -0.25 D, -0.5 D, and -0.75 D.

Results:

Of the 151 subjects bilaterally implanted with DFT015 at 6mo, 19 subjects met the definition of minmonovision. Compared to the non-monovision group, UIVA and UNVA improved nearly a line (-0.08 logMAR) and with no meaningful change in UDVA (0.02 logMAR). Twenty percent more subjects with minimonovision reported never needing spectacles for intermediate and near tasks. Bench halos remained monofocal-like for the monovision simulations and the % not bothered by visual disturbances remained high in the minimonovision group (e.g. 73% not bothered by starbursts in both minimonovision and non-monovision groups).

Conclusions:

Bilateral implantation of this non-diffractive extended vision IOL with minimonovision improves near and intermediate vision without affecting distance vision while maintaining the monofocal-like visual disturbance profile.

Financial Disclosure:

is employed by a for profit company with an interest in the subject of the presentation, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented